Arena Pharmaceuticals And Beacon Discovery Expand Strategic Relationship Focusing On Multiple Immune And Inflammatory Targets

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Beacon Discovery today announced that they entered into a strategic multi-year partnership (Project Cabrillo) aimed at building novel medicines across a range

Benzinga · 01/02/2020 13:31

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Beacon Discovery today announced that they entered into a strategic multi-year partnership (Project Cabrillo) aimed at building novel medicines across a range of G protein-coupled receptor (GPCR) targets.

Under the terms of the deal, Beacon will be responsible for drug discovery activities. Arena will focus on developing and commercializing promising novel compounds in a variety of immune and inflammatory diseases that complement their first- or best-in-class pipeline. Financial terms of the agreement have not been disclosed.